Drug-resistant tuberculosis (DR-TB) is a global public health crisis. Isoniazid-resistant TB (INH-R TB), which is resistant to isoniazid but sensitive to rifampin, is the most common form of drug-resistant TB in the world, with an estimated 1.5 million cases occurring annually. In spite of the high burden of INH-R TB, there are very limited data from clinical trials to guide treatment, and current guidelines are based largely on observational studies, systematic reviews, meta-analyses, and expert opinion. Multi-drug resistant TB (MDR-TB), which is resistant to both isoniazid and rifampin, causes about 490,000 cases annually; of these, an estimated 6.2% are extensively drug-resistant (XDR-TB), with additional resistance to both fluoroquinolones and second-line injectable medications. Standard treatment for MDR-TB is lengthy (minimum of 18 months) and associated with a high rate of adverse events. However, there have recently been major advances in the treatment of MDR-TB, with the implementation of shorter regimens and new and repurposed drugs. This talk will review rapid testing for DR-TB, and the evidence base to guide treatment, including new drug regimens and data from ongoing and planned trials, with a particular focus on INH-R TB, MDR-TB, and XDR-TB.